2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125719
    Clevudine triphosphate
    		Inhibitor
    Clevudine triphosphate is a thymidine analog. Clevudine triphosphate has anti-human hepatitis B virus (HBV) activity.
    Clevudine triphosphate
  • HY-117925
    Personalised postprandial-targeting
    		Inhibitor
    Personalised postprandial-targeting is a way to modulate water-heme interactions with activity against low-spin P450 complexes. Personalised postprandial-targeting is able to maintain the axial water ligands of CYP2C9 even in the presence of inhibitors. Personalised postprandial-targeting also allows the hydrogen atoms of the axial water ligands to be observed by EPR spectroscopy, providing insights into the enzyme active site.
    Personalised postprandial-targeting
  • HY-145713A
    GS-8873 TFA
    		Inhibitor
    GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys.
    GS-8873 TFA
  • HY-115430
    Tenofovir disoproxil aspartate
    Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.
    Tenofovir disoproxil aspartate
  • HY-113586
    Besifovir Dipivoxil
    		Inhibitor
    Besifovir Dipivoxil (LB-80380), an analog of guanosine monophosphate, is an acyclic nucleotide phosphonate with antiviral effect. Besifovir Dipivoxil is rapidly converted by the liver and intestine to the intermediate metabolite LB80331 via the esterification process, subsequently phosphorylated into the di- and triphosphate forms, which act as antiviral DNA synthesis inhibitors. Besifovir Dipivoxil is promising for research of chronic hepatitis B.
    Besifovir Dipivoxil
  • HY-B0250S2
    Lamivudine-13C,15N3
    		Inhibitor
    Lamivudine-13C,15N3 (BCH-189-13C,15N3) is 13C and 15N labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>13</sup>C,<sup>15</sup>N<sub>3</sub>
  • HY-W074930R
    (S)-Tenofovir (Standard)
    		Inhibitor
    (S)-Tenofovir (Standard) is the analytical standard of (S)-Tenofovir. This product is intended for research and analytical applications. (S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
    (S)-Tenofovir (Standard)
Cat. No. Product Name / Synonyms Application Reactivity